Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Andean Precious Metals Corp. (APM:CA) Q4 2025 Earnings Call Transcript

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens” in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research.

NEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Instant NanoBiosensors Co., Ltd. (“INB”), a developer of cutting-edge biosensor platforms designed to improve biomedical research and diagnostic processes through simple, reliable, and affordable detection solutions, today announced a collaboration between DiamiR and INB to validate INB's automated APOE testing platform for clinical use in DiamiR's CLIA-certified, CAP-accredited clinical laboratory.

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online.

Andean Precious Metals Corp. ( APM:CA ) Q3 2025 Earnings Call November 12, 2025 9:00 AM EST Company Participants Amanda Mallough Alberto Morales - Founder, CEO & Executive Chairman Yohann Bouchard - President & Director Juan Sandoval - Chief Financial Officer Dom Kizek Conference Call Participants Omeet Singh - SCP Resource Finance LP, Research Division Allison Carson - Desjardins Securities Inc., Research Division Ben Pirie - Atrium Research Corporation Presentation Operator Hello, and welcome to the Andean Precious Metals Third Quarter Conference Call and Webcast. [Operator Instructions] I would now like to turn the conference over to Amanda Mallough, Director of Investor Relations.

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it received formal written notification from The Nasdaq Stock Market, LLC (“Nasdaq”) confirming that the company has regained compliance with Nasdaq's minimum bid price requirement.

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology  and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.